BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 15546128)

  • 1. Reactivation of Epstein-Barr virus from latency.
    Amon W; Farrell PJ
    Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
    Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
    J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
    Beck Z; Illés A; Keresztes K; Bessenyei B; Szöllosi Z; Kis A; Oláh E
    Orv Hetil; 2006 Aug; 147(33):1539-44. PubMed ID: 17037676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecular link between malaria and Epstein-Barr virus reactivation.
    Chêne A; Donati D; Guerreiro-Cacais AO; Levitsky V; Chen Q; Falk KI; Orem J; Kironde F; Wahlgren M; Bejarano MT
    PLoS Pathog; 2007 Jun; 3(6):e80. PubMed ID: 17559303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
    Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
    Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.
    Chia MC; Leung A; Krushel T; Alajez NM; Lo KW; Busson P; Klamut HJ; Bastianutto C; Liu FF
    Clin Cancer Res; 2008 Feb; 14(4):984-94. PubMed ID: 18281530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent and lytic Epstein-Barr virus replication strategies.
    Tsurumi T; Fujita M; Kudoh A
    Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
    Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
    Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus and oncogenesis: from latent genes to tumours.
    Young LS; Murray PG
    Oncogene; 2003 Aug; 22(33):5108-21. PubMed ID: 12910248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus permissively infects human syncytiotrophoblasts in vitro and induces replication of human T cell leukemia-lymphoma virus type I in dually infected cells.
    Tóth FD; Aboagye-Mathiesen G; Nemes J; Liu X; Andirkó I; Hager H; Zdravkovic M; Szabó J; Kiss J; Aranyosi J; Ebbesen P
    Virology; 1997 Mar; 229(2):400-14. PubMed ID: 9126252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus: 40 years on.
    Young LS; Rickinson AB
    Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
    Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
    Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lytic cycle switches of oncogenic human gammaherpesviruses.
    Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
    Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection.
    Kubota N; Wada K; Ito Y; Shimoyama Y; Nakamura S; Nishiyama Y; Kimura H
    J Virol Methods; 2008 Jan; 147(1):26-36. PubMed ID: 17870188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells.
    Liu SF; Wang H; Lin XC; Xiang H; Deng XY; Li W; Tang M; Cao Y
    Cell Biol Int; 2008 Aug; 32(8):1006-13. PubMed ID: 18579417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers.
    Evans TJ; Brooks L; Farrell PJ
    Gene Ther; 1997 Mar; 4(3):264-7. PubMed ID: 9135741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
    Kelly G; Bell A; Rickinson A
    Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
    Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
    Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.